Tag

Mhc I

All articles tagged with #mhc i

science25 days ago•18 min saved

Broadening covalent neoantigens to mobilize immune defense

A new platform shows that cysteine-reactive covalent modifications of intracellular proteins can be processed and presented as covalent neoantigens on MHC class I, and a bioorthogonal strategy enables immune-cell engagement by linking these neoantigens to recruiters that activate CD32- and CD3-expressing reporters, thereby expanding the repertoire of covalent neoantigens and offering a general approach to immune targeting of haptenated neoepitopes.

via Nature|

#bioorthogonal-chemistry #covalent-neoantigens #cysteine-reactive-probes

health-and-medicine1 month ago•7 min saved

RNA-targeting CRISPR revives immune visibility of prostate cancer

Researchers used an RNA-targeting CRISPR-Cas13 tool to lengthen the SPSB1 mRNA in prostate cancer cells, lowering SPSB1 protein levels and restoring the MHC-I immune signal. This made tumors more recognizable to T cells, enhancing immune checkpoint therapy in mice with no detectable off-target effects, and potentially extending to other immune-cold cancers.

via ScienceDaily|

#crispr #health-and-medicine #immunotherapy

science2 months ago•13 min saved

When cancer hides MHC I, NK cells may strike back

For decades, MHC class I was seen as the marker used by T cells to detect cancer, but tumors that downregulate MHC I evade T cells while potentially exposing themselves to natural killer (NK) cells that detect 'missing self.' NK cells are inhibited by MHC I through receptors like KIRs, so loss of MHC I can lift that brake, creating a vulnerability. In practice, tumors face barriers to NK cell infiltration and can become exhausted, making responses inconsistent. Researchers are pursuing NK cell–based therapies and cytokine strategies to exploit MHC I loss, particularly in cancers resistant to checkpoint inhibitors, with the goal of turning this paradox into a new therapeutic avenue while continuing to tackle delivery and safety challenges.

via Space Daily|

#cancer-immunology #immunotherapy #mhc-i

science2 months ago•6 min saved

Hidden Cancer IDs Spotted by Helper T Cells, Opening New Immunotherapy Avenues

New findings show cancer cells that downregulate MHC I can still be targeted by CD4+ T cells via ferroptosis, expanding the role of helper T cells in cancer immunity and potentially strengthening immunotherapies beyond the traditional CD8+ T cell focus.

via ScienceAlert|

#cancer-immunotherapy #cd4-t-cells #cd8-t-cells